adra2c Antibody

What is ADRA2C and what research applications utilize ADRA2C antibodies?

ADRA2C (Alpha-2C adrenergic receptor) is a G-protein coupled receptor belonging to the G-protein coupled receptor 1 family. It plays significant roles in presynaptic inhibition of neurotransmitter release, particularly in the central nervous system. Research applications for ADRA2C antibodies include characterization of receptor expression patterns in neuropsychiatric disorders like schizophrenia, investigation of adrenergic signaling pathways, analysis of drug mechanism of action, and epigenetic studies examining histone modifications at the ADRA2C promoter region. These antibodies are especially valuable in neuroscience research as ADRA2C represents a potential therapeutic target for neurological and psychiatric disorders .

What types of ADRA2C antibodies are available for research applications?

Several types of ADRA2C antibodies are available, each with specific characteristics suitable for different experimental approaches:

These antibodies are typically generated against synthetic peptides derived from specific regions of human ADRA2C. For instance, the A05170 antibody targets amino acids 336-385 of the human sequence, contributing to its specificity profile .

How do I select the appropriate ADRA2C antibody for my research model?

When selecting an ADRA2C antibody, consider these critical factors to ensure experimental success:

First, verify species cross-reactivity. Most commercial ADRA2C antibodies (including A05170 and ARG44332) react with human, mouse, and rat proteins, but validation in other species may require preliminary testing. For example, one researcher inquired about goat tissue reactivity, which had not been previously validated .

Second, confirm application compatibility. Some antibodies are validated only for certain applications - A05170 is primarily recommended for Western blot, while ARG44332 is validated for both Western blot and immunohistochemistry on paraffin-embedded sections .

Third, consider clonality implications. Monoclonal antibodies offer high specificity for a single epitope but may be more sensitive to epitope modifications. Polyclonal antibodies recognize multiple epitopes, potentially providing greater detection sensitivity with potentially reduced specificity .

Fourth, review validation data and published studies using your antibody of interest to assess performance in similar experimental contexts. This approach helps predict antibody behavior in your specific research model .

What are the optimal conditions for using ADRA2C antibodies in Western blot applications?

For optimal Western blot detection of ADRA2C, follow these evidence-based recommendations:

For sample preparation, use RIPA or similar lysis buffers containing protease inhibitors. Since ADRA2C is a membrane protein, inclusion of appropriate detergents (0.1-1% SDS) improves extraction efficiency. Avoid repeated freeze-thaw cycles of protein samples to prevent degradation .

For antibody dilutions, the recommended range for antibodies like A05170 is 1:500-1:2000. This should be optimized for your specific sample type by testing a dilution series .

When conducting electrophoresis, use 10-12% polyacrylamide gels for optimal separation of ADRA2C, which has a calculated molecular weight of approximately 49.5 kDa but typically appears around 39 kDa in Western blots. This size discrepancy is common for membrane proteins due to their hydrophobicity and post-translational modifications .

For antibody incubation, overnight primary antibody incubation at 4°C generally provides optimal binding. Use anti-rabbit HRP conjugates as secondary antibodies (typically at 1:5000-1:10000 dilution), followed by chemiluminescent detection .

Always include positive control samples (such as brain tissue lysates) and consider blocking peptide experiments to validate specificity .

What fixation and processing methods are recommended for immunohistochemical detection of ADRA2C?

For effective immunohistochemical detection of ADRA2C in tissue sections, proper fixation and processing are critical:

Paraformaldehyde (PFA) fixation is generally recommended due to its superior tissue penetration. Importantly, PFA should be freshly prepared before use to prevent conversion to formalin, which has different fixation properties. When responding to a researcher's question about fixation methods, Boster Scientific Support specifically recommended PFA for this reason .

For antigen retrieval, heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) has proven effective for ADRA2C detection. The specific retrieval method may need optimization depending on tissue type and fixation duration .

When staining, include appropriate blocking steps with both protein blocking (5% BSA or serum) and peroxidase blocking. Primary antibody incubation is typically more effective when performed overnight at 4°C, which enhances specific binding while minimizing background .

For challenging tissues with low ADRA2C expression, signal amplification systems may be necessary. Options include tyramide signal amplification or polymer-based detection systems that provide enhanced sensitivity compared to traditional methods .

How can I validate the specificity of ADRA2C antibodies in my experimental system?

Rigorous validation of ADRA2C antibody specificity is essential for generating reliable data. Implement these validation strategies:

Blocking peptide experiments serve as a critical specificity test. Pre-incubate the ADRA2C antibody with the immunizing peptide (available for antibodies like A05170, as confirmed by Boster Scientific Support in response to a customer inquiry), then run parallel assays with blocked and unblocked antibody. Specific signals should be significantly reduced or eliminated in the blocked condition .

Include appropriate controls in all experiments. Use tissues known to express ADRA2C (such as brain tissues) as positive controls and tissues with minimal ADRA2C expression as negative controls. The observed molecular weight should be consistent with expectations (approximately 39 kDa for ADRA2C, though the calculated weight is 49.5 kDa) .

For definitive validation, consider genetic approaches. ADRA2C knockdown (siRNA) or knockout (CRISPR-Cas9) models provide powerful tools to confirm antibody specificity, as the signal should be reduced or absent in these models .

Testing multiple antibodies targeting different epitopes of ADRA2C can strengthen confidence in your findings. Consistent results across different antibodies significantly increase the reliability of your observations .

How does ADRA2C gene expression differ in neuropsychiatric conditions like schizophrenia?

Research on ADRA2C expression in schizophrenia has revealed significant alterations that may contribute to disease pathophysiology and treatment responses:

ADRA2C mRNA expression is upregulated by approximately 53% in the dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia compared to matched controls, regardless of antipsychotic treatment status. This contrasts with ADRA2A expression, which shows selective upregulation (+93%) only in antipsychotic-treated schizophrenia subjects .

The differential regulation of ADRA2C appears to be disease-related rather than medication-induced, as it is present in both antipsychotic-free and antipsychotic-treated subjects. This suggests distinct pathophysiological mechanisms affecting different adrenergic receptor subtypes in schizophrenia .

Animal studies with clozapine treatment demonstrate increased Adra2c mRNA expression in rat brain cortex, suggesting that some antipsychotics may have direct effects on this receptor subtype independent of disease state. These experimental models provide valuable tools for investigating the pharmacological modulation of adrenergic signaling .

These findings highlight the importance of studying multiple adrenergic receptor subtypes simultaneously when investigating neuropsychiatric disorders, as they may show distinct patterns of dysregulation with different functional implications .

What epigenetic modifications regulate ADRA2C expression and how can they be studied?

ADRA2C expression is regulated by various epigenetic mechanisms, particularly histone post-translational modifications (PTMs) that can be studied through specialized techniques:

Research has identified several histone modifications at the ADRA2C promoter region that influence gene expression. These include permissive marks like H3K4me3 (histone H3 trimethylated at lysine 4), H3ac, H3K9ac, and H3K27ac, as well as repressive marks such as H3K27me3 (histone H3 trimethylated at lysine 27). Additional modifications include H4K5ac and H4K16ac on histone H4 .

Chromatin immunoprecipitation (ChIP) is the primary method for studying these modifications. In this technique, chromatin is crosslinked, fragmented, and immunoprecipitated using antibodies against specific histone modifications. The precipitated DNA is then analyzed by qPCR using primers targeting the ADRA2C promoter region .

Analysis of these epigenetic patterns has revealed important insights into ADRA2C regulation. For example, studies in schizophrenia have observed bivalent chromatin states (presence of both activating H3K4me3 and repressive H3K27me3) at the ADRA2C promoter. Additionally, enhanced H4K16ac at the ADRA2C promoter may trigger upregulation in antipsychotic-treated subjects .

When studying these epigenetic mechanisms, data normalization using appropriate reference genes (e.g., GAPDH, RPS13 for human; Gapdh, Rps29 for animal models) is critical for accurate interpretation. The ΔΔCt method is commonly employed for quantifying relative enrichment of histone modifications .

How do antipsychotic treatments affect ADRA2C expression?

Antipsychotic treatments have complex effects on ADRA2C expression, with both human and animal studies providing insights into the mechanisms:

Human postmortem studies have found that ADRA2C mRNA is upregulated (+53%) in schizophrenia subjects regardless of antipsychotic treatment. This contrasts with ADRA2A, which shows selective upregulation (+93%) only in antipsychotic-treated subjects. These differential patterns suggest distinct regulatory mechanisms for different adrenergic receptor subtypes .

Animal studies provide complementary evidence, demonstrating that both acute and chronic clozapine treatment increase Adra2c mRNA expression in rat brain cortex. This suggests direct effects of atypical antipsychotics on Adra2c gene regulation that may be independent of disease state .

The molecular mechanisms underlying these expression changes involve epigenetic regulation. Antipsychotic treatment may modulate histone modifications at the ADRA2C promoter, particularly H4K16ac, which has been associated with expression changes. Additionally, the presence of bivalent chromatin states (H3K4me3 and H3K27me3) at the ADRA2C promoter may create a poised state that is responsive to antipsychotic treatment .

For rigorous investigation of these effects, researchers employ various methodological approaches, including qRT-PCR for mRNA quantification (normalized to reference genes like GAPDH and RPS13), ChIP assays to examine histone modification changes, and controlled drug administration protocols in animal models .

Why might I see multiple bands when using ADRA2C antibodies in Western blot?

Multiple bands in ADRA2C Western blots can arise from several sources, and proper interpretation requires systematic analysis:

Post-translational modifications significantly impact ADRA2C detection. As a G-protein coupled receptor, ADRA2C undergoes glycosylation and other modifications that can alter its migration in SDS-PAGE. While the calculated molecular weight is approximately 49.5 kDa, the observed molecular weight is typically around 39 kDa, as noted in product information .

Protein degradation during sample preparation can generate fragment bands. To minimize this, use fresh samples, add protease inhibitors to lysis buffers, and avoid repeated freeze-thaw cycles. Boster Scientific Support specifically recommends storing the antibody at -20°C with cryoprotectants like glycerol to maintain integrity .

Non-specific binding can occur, particularly with polyclonal antibodies. To confirm which bands represent specific ADRA2C detection, blocking peptide experiments are invaluable. By pre-incubating the antibody with the immunizing peptide, specific bands should be eliminated or substantially reduced .

For optimal results, optimize sample preparation conditions, including denaturation parameters and detergent concentration. Additionally, adjust blocking conditions (try both milk and BSA as blocking agents) and antibody dilution to improve specificity .

How can I improve detection of ADRA2C in tissues with low expression levels?

When working with tissues having low ADRA2C expression, several strategies can enhance detection sensitivity:

Signal amplification techniques provide significant sensitivity improvements. Tyramide signal amplification (TSA) can increase sensitivity 10-100 fold, while polymer-based detection systems offer better results than traditional ABC methods. For Western blots, enhanced chemiluminescence (ECL) substrates with higher sensitivity can improve detection of low-abundance targets .

Optimizing antibody incubation parameters can dramatically improve results. Extended primary antibody incubation (overnight at 4°C or longer) and carefully titrated antibody concentration increases binding opportunity without elevating background. One researcher specifically asked about antibody optimization for kidney samples, indicating this is a common challenge with ADRA2C detection .

Sample enrichment approaches can concentrate the target protein. Consider subcellular fractionation to isolate membrane proteins, as ADRA2C is a membrane-bound receptor. For heterogeneous tissues, techniques like laser capture microdissection can isolate specific cell populations with higher receptor expression .

Alternative detection methods may offer superior sensitivity for challenging samples. Proximity ligation assay (PLA) provides highly sensitive protein detection, while parallel analysis of mRNA using techniques like RNAscope can support protein findings through correlation of transcript and protein levels .

Can ADRA2C antibodies be modified for specialized applications?

ADRA2C antibodies can be adapted for specialized applications through various modifications, though these require careful consideration:

Biotin conjugation is feasible for applications requiring streptavidin-based detection systems. When a researcher inquired about conjugating anti-AR alpha2C antibody (A05170) with biotin, Boster Scientific Support advised that while possible, the antibody formulation would need modification. The standard formulation contains BSA and sodium azide, which can interfere with conjugation chemistry .

For long-term storage of modified antibodies, cryoprotectants are essential. Rather than storing in PBS alone (which can lead to degradation), Boster Scientific Support recommended including glycerol and/or trehalose. These molecules provide stability without interfering with conjugation chemistry .

For carrier-free preparations needed for conjugation, specialized formulations can be requested. Companies can provide ADRA2C antibodies without BSA or sodium azide, specifically formulated with cryoprotectants that won't interfere with conjugation reactions .

When considering antibody modifications, it's crucial to validate the modified antibody to ensure retained specificity and sensitivity. This validation should include comparison with the unmodified antibody using appropriate positive controls .

How should I quantify and analyze ADRA2C expression data?

For robust quantification and analysis of ADRA2C expression, employ these methodological approaches:

When quantifying mRNA expression, the ΔΔCt method is standard practice. As demonstrated in the literature: ΔΔCt = (Ct(ADRA2C) sample – Ct(reference gene) sample) – (Ct(ADRA2C) reference sample – Ct(reference gene) reference sample), with relative expression calculated as 2^(-ΔΔCt). Multiple reference genes should be used (e.g., GAPDH, RPS13 for human; Gapdh, Rps29 for rodents) to ensure reliable normalization .

For protein quantification by Western blot, densitometric analysis of band intensity should be normalized to appropriate loading controls. While the calculated molecular weight of ADRA2C is 49.5 kDa, the observed molecular weight is typically around 39 kDa, so correct band identification is crucial .

Statistical analysis should be tailored to your experimental design. For comparing two groups (e.g., control vs. disease), t-tests are appropriate for normally distributed data, while Mann-Whitney U tests serve non-normally distributed data. For multiple groups, ANOVA with appropriate post-hoc tests should be employed. Always report effect sizes alongside p-values to indicate biological significance .

When analyzing immunohistochemical data, digital image analysis with standardized parameters improves objectivity. Measurements may include optical density for DAB staining or fluorescence intensity for immunofluorescence. Region of interest (ROI) standardization and blind analysis prevent bias in quantification .

How should I interpret differences between ADRA2C protein levels and gene expression data?

Discrepancies between ADRA2C protein and mRNA levels are common and may reflect important biological mechanisms rather than technical limitations:

Post-transcriptional regulation significantly impacts the relationship between mRNA and protein levels. While studies have shown upregulation of ADRA2C mRNA in conditions like schizophrenia (+53% in DLPFC), protein levels may not change proportionally due to translation efficiency, protein stability, or post-translational modifications .

Temporal dynamics must be considered when comparing mRNA and protein measurements. mRNA changes typically precede protein alterations, so time-course experiments can help establish the relationship between transcript and protein expression changes .

Epigenetic regulation creates another layer of complexity. Research has identified bivalent chromatin at the ADRA2C promoter region in schizophrenia (depicted by increased permissive H3K4me3 and repressive H3K27me3), which may create a poised state affecting the relationship between active transcription and protein production .

When analyzing such data, present mRNA and protein results separately with appropriate normalization, then discuss potential mechanisms for discrepancies. Correlation analysis between mRNA and protein levels can quantify their relationship, though strong correlations should not always be expected .